AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 78 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $17,488 | -49.3% | 60,302 | -21.3% | 0.00% | – |
Q4 2022 | $34,460 | -13.8% | 76,594 | 0.0% | 0.00% | – |
Q3 2022 | $40,000 | +2.6% | 76,594 | 0.0% | 0.00% | – |
Q2 2022 | $39,000 | -77.8% | 76,594 | 0.0% | 0.00% | -100.0% |
Q1 2022 | $176,000 | -51.6% | 76,594 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $364,000 | -12.3% | 76,594 | +46.7% | 0.00% | 0.0% |
Q3 2021 | $415,000 | +14.3% | 52,204 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $363,000 | -12.1% | 52,204 | 0.0% | 0.00% | -50.0% |
Q1 2021 | $413,000 | +0.5% | 52,204 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $411,000 | +11.1% | 52,204 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $370,000 | -23.4% | 52,204 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $483,000 | +280.3% | 52,204 | +91.9% | 0.00% | +100.0% |
Q1 2020 | $127,000 | -38.9% | 27,204 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $208,000 | -0.5% | 27,204 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $209,000 | +12.4% | 27,204 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $186,000 | -15.1% | 27,204 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $219,000 | +7.4% | 27,204 | 0.0% | 0.00% | 0.0% |
Q4 2018 | $204,000 | -21.5% | 27,204 | 0.0% | 0.00% | -50.0% |
Q3 2018 | $260,000 | -9.7% | 27,204 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $288,000 | +6.7% | 27,204 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $270,000 | +342.6% | 27,204 | +142.8% | 0.00% | – |
Q4 2017 | $61,000 | +10.9% | 11,204 | 0.0% | 0.00% | – |
Q3 2017 | $55,000 | +27.9% | 11,204 | 0.0% | 0.00% | – |
Q2 2017 | $43,000 | – | 11,204 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |